Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.
source https://www.sciencedaily.com/releases/2025/01/250125152749.htm
Pharmaceuticals face 100% tariffs in US - unless firms strike a deal
-
The order does not affect generic medicines, the most commonly used in the
US.
source
https://www.bbc.com/news/articles/cx29kke01gpo?at_medium=RSS&at_camp...
22 hours ago
Welcome to the 'The Fact Factory' friends. Its an interesting Hot Spot which brings to you amazing and little known facts from all over the world. So, sit back, take a tour around the world and enjoy the trivia.
No comments:
Post a Comment